<DOC>
	<DOCNO>NCT01774474</DOCNO>
	<brief_summary>Cystoid macular edema ( CME ) common cause vision loss cataract surgery . In last year , several new treatment try address problem CME cataract surgery diabetic non-diabetic patient . The investigator perform large RCT aim provide definite evidence-based recommendation clinical guideline prevent occurrence CME cataract surgery patient without diabetes mellitus ( DM ) .</brief_summary>
	<brief_title>PRevention Macular EDema After Cataract Surgery</brief_title>
	<detailed_description>The objective study evaluate effect different preventive strategy occurrence CME cataract surgery non-diabetic diabetic patient . The design study multicentre randomise controlled clinical trial . The study population consist 926 non-diabetic patient 209 patient diabetes mellitus ( DM ) require cataract surgery least one eye . All patient receive phacoemulsification cataract placement posterior chamber intraocular lens ( IOL ) . In non-diabetic population , patient receive either bromfenac 0.09 % eye drop twice daily start two day surgery continue 2 week postoperative , dexamethasone 0.1 % eye drop four time daily start two day surgery continue four time daily first postoperative week one drop less per day every follow week combination drug . In diabetic population patient receive either : - Topical bromfenac 0.09 % dexamethasone 0.1 % aforementioned dose ; - Topical bromfenac 0.09 % dexamethasone 0.1 % aforementioned dose subconjunctival injection 40 mg triamcinolone acetonide ; - Topical bromfenac 0.09 % dexamethasone 0.1 % aforementioned dose intravitreal injection 1.25 mg bevacizumab ; - Topical bromfenac 0.09 % dexamethasone 0.1 % aforementioned dose , subconjunctival injection 40 mg triamcinolone acetonide intravitreal injection 1.25 mg bevacizumab . The primary endpoint change central subfield mean macular thickness 1 mm area ( central subfield macular thickness , CSMT ) compare baseline within first 6 week postoperative . The secondary endpoint occurrence postoperative clinically significant macular edema ( CSME ) within 12 week postoperatively . Other study endpoint mean CDVA logMAR 6 week 12 week postoperatively ; OCT measure average retinal thickness central inner circle ( 3mm ) , out circle ( 6mm ) , macular volume 6 week 12 week postoperatively ; intraocular pressure 6 week 12 week postoperatively . In case clinically significant macular edema , treatment initiated effect part evaluation 12 week . Medical data patient develop macular edema study check least 6 month surgery .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Capsule Opacification</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Bromfenac</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>All patient undergo routine phacoemulsification ( one eye per patient ) willing and/or able comply schedule visit study procedure . able communicate properly understand instruction . accept possible offlabel use intravitreal bevacizumab and/or subconjunctival preservativefree TA . Exclusion criterion different nondiabetic diabetic patient . All ophthalmic exclusion criterion applicable study eye , unless state otherwise . General exclusion criterion participation study : 1. age 21 year old ; 2. participation another clinical study ; 3. posttraumatic cataract ; 4. combine surgery ; 5. functional monoculus ; 6. previous ocular surgery ; 7. progressive glaucoma severe visual field defect , use antiglaucomatous medication steroidinduced IOP elevation require IOPlowering treatment ; 8 . IOP ≥ 25 mmHg ; 9. history intraocular inflammation uveitis ; 10. history pseudoexfoliation syndrome , expect cause peroperative complication ; 11. history Fuchs ' endothelial dystrophy cornea guttata 3+ ; 12. history retinal vein occlusion ; 13. macular pathology might influence VA , DME ; 14. use intravitreal bevacizumab ranibizumab previous 6 week intravitreal aflibercept previous 10 week ; 15. use intra periocular corticosteroid injection previous 4 month ; 16. current use topical NSAIDs corticosteroid ; 17. use systemic corticosteroid ( ≥ 20 mg prednisolone equivalence ) ; 18. history relevant adverse event , include serious adverse event ( SAE ) , occur administration NSAIDs , acetylsalicylic acid , sodium sulphite , corticosteroid bevacizumab ; 19. contraindication use topical NSAIDs , topical subconjunctival corticosteroid intravitreal bevacizumab related drug ; Nondiabetic patient history CME exclude participation study . Additionally , diabetic patient exclude participation case : 1. macular edema CSMT ≥450 µm ; 2. severe NPDR proliferative DR require panretinal photocoagulation vitrectomy ; 3. vitreous haemorrhage present preoperative visit ( ) ; 4. cerebrovascular accident ( CVA ) , myocardial infarction ( MI ) thromboembolic event previous 3 month ; 5. history recurrent thromboembolic event ; 6. history severe systemic bleeding previous 3 month ; 7. major surgery previous 3 month ; 8. history glaucoma ;</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Prevention</keyword>
</DOC>